دورية أكاديمية
Synthesis, physicochemical characterization, toxicity and efficacy of a PEG conjugate and a hybrid PEG conjugate nanoparticle formulation of the antibiotic moxifloxacin.
| العنوان: | Synthesis, physicochemical characterization, toxicity and efficacy of a PEG conjugate and a hybrid PEG conjugate nanoparticle formulation of the antibiotic moxifloxacin. |
|---|---|
| المؤلفون: | Tshweu LL; Biopolymer Modification & Therapeutics Lab, Chemicals Cluster, Council for Scientific and Industrial Research Pretoria 0001 South Africa mbalogun@csir.co.za mohammedbalogun@tuks.co.za.; Department of Chemistry, University of Pretoria Pretoria South Africa., Shemis MA; Biochemistry & Molecular Biology Department, Theodor Bilharz Research Institute Warak El-Hadar, Kornish El-Nile, P.O. Box 30, Imbaba 12411-Giza Egypt., Abdelghany A; Biochemistry & Molecular Biology Department, Theodor Bilharz Research Institute Warak El-Hadar, Kornish El-Nile, P.O. Box 30, Imbaba 12411-Giza Egypt., Gouda A; Biochemistry & Molecular Biology Department, Theodor Bilharz Research Institute Warak El-Hadar, Kornish El-Nile, P.O. Box 30, Imbaba 12411-Giza Egypt., Pilcher LA; Department of Chemistry, University of Pretoria Pretoria South Africa., Sibuyi NRS; DST/Mintek Nanotechnology Innovation Centre, Biolabels Node, Department of Biotechnology, University of the Western Cape Cape Town South Africa., Meyer M; DST/Mintek Nanotechnology Innovation Centre, Biolabels Node, Department of Biotechnology, University of the Western Cape Cape Town South Africa., Dube A; Infectious Disease Nanomedicine Research Group, School of Pharmacy, University of the Western Cape Cape Town South Africa., Balogun MO; Biopolymer Modification & Therapeutics Lab, Chemicals Cluster, Council for Scientific and Industrial Research Pretoria 0001 South Africa mbalogun@csir.co.za mohammedbalogun@tuks.co.za. |
| المصدر: | RSC advances [RSC Adv] 2020 May 26; Vol. 10 (34), pp. 19770-19780. Date of Electronic Publication: 2020 May 26 (Print Publication: 2020). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101581657 Publication Model: eCollection Cited Medium: Internet ISSN: 2046-2069 (Electronic) Linking ISSN: 20462069 NLM ISO Abbreviation: RSC Adv Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Cambridge [England] : Royal Society of Chemistry, [2011]- |
| مستخلص: | Antibiotic resistance is increasing at such an alarming rate that it is now one of the greatest global health challenges. Undesirable toxic side-effects of the drugs lead to high rates of non-completion of treatment regimens which in turn leads to the development of drug resistance. We report on the development of delivery systems that enable antibiotics to be toxic against bacterial cells while sparing human cells. The broad-spectrum fluoroquinolone antibiotic moxifloxacin (Mox) was successfully conjugated to poly(ethylene glycol) (PEG) which was further encapsulated into the hydrophobic poly(ε-caprolactone) (PCL) nanoparticles (NPs) with high efficiency, average particle size of 241.8 ± 4 nm and negative zeta potential. Toxicity against erythrocytes and MDBK cell lines and drug release in human plasma were evaluated. Hemocompatibility and reduced cytotoxicity of the PEG-Mox and PCL(PEG-Mox) NPs were demonstrated in comparison to free Mox. Antimicrobial activity was assessed against drug sensitive and resistant: Staphylococcus aureus , Escherichia coli , Pseudomonas aeruginosa and Klebsiella pneumoniae . The antibacterial activity of Mox was largely maintained after conjugation. Our data shows that the toxicity of Mox can be effectively attenuated while, in the case of PEG-Mox, retaining significant antibacterial activity. At the conditions employed in this study for antimicrobial activity the encapsulated conjugate (PCL(PEG-Mox) NPs) did not demonstrate, conclusively, significant antibacterial activity. These systems do, however, hold promise if further developed for improved treatment of bacterial infections. Competing Interests: There are no conflicts to declare. (This journal is © The Royal Society of Chemistry.) |
| References: | J Drug Target. 1994;2(4):341-7. (PMID: 7858959) Eur J Pharm Biopharm. 2009 Feb;71(2):196-206. (PMID: 18762253) Pharm Res. 2018 Oct 15;35(12):237. (PMID: 30324329) Drug Dev Ind Pharm. 1999 Apr;25(4):471-6. (PMID: 10194602) Antimicrob Agents Chemother. 2006 Jun;50(6):1982-8. (PMID: 16723555) Pharm Dev Technol. 2011 Jun;16(3):187-200. (PMID: 20429826) J Antimicrob Chemother. 2006 Jun;57(6):1100-9. (PMID: 16595638) J Control Release. 2011 Dec 10;156(2):128-45. (PMID: 21763369) PLoS One. 2016 Jun 03;11(6):e0156690. (PMID: 27257956) Nat Rev Microbiol. 2019 Jan;17(1):3. (PMID: 30467331) Pharm Res. 2009 May;26(5):1025-58. (PMID: 19107579) J Colloid Interface Sci. 2016 Dec 1;483:132-138. (PMID: 27552421) Carbohydr Polym. 2016 Jan 20;136:1297-306. (PMID: 26572474) Curr Protoc Pharmacol. 2003 Feb;Chapter 7:Unit 7.6. (PMID: 22294085) J Biomed Mater Res A. 2015 Nov;103(11):3599-611. (PMID: 25976509) Tuberculosis (Edinb). 2008 Mar;88(2):127-31. (PMID: 18486050) Int J Pharm. 2008 Dec 8;364(2):298-327. (PMID: 18621492) Nat Rev Drug Discov. 2019 Apr;18(4):273-294. (PMID: 30542076) J Control Release. 2019 Nov 28;314:116-124. (PMID: 31647980) |
| تواريخ الأحداث: | Date Created: 20220506 Latest Revision: 20220716 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9054125 |
| DOI: | 10.1039/c9ra10872f |
| PMID: | 35520420 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!